Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

LONDON (Reuters) – GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis’s Sandoz division.

Source: Reuters Medical News